Peter Borchmann
YOU?
Author Swipe
Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma Open
We report the 5-year analysis of tisagenlecleucel in 115 infused patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) from the single-arm, open-label, multicenter, global, phase II JULIET trial (ClinicalTrials.gov identifie…
View article: External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials
External validation of the early-stage classic Hodgkin lymphoma (cHL) international prognostication index (E-HIPI) in the german Hodgkin study group (GHSG) unfavorable clinical trials Open
Background: Although progression-free survival (PFS) in early-stage (ES) classic Hodgkin Lymphoma (cHL) is high, there remains a subset of patients (pts) at higher risk of worse outcomes, particularly in those with unfavorable risk disease…
View article: Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL Open
Introduction: In the primary analysis of TRANSCEND FL (NCT04245839), an open-label, pivotal study, liso-cel showed high response rates and favorable safety in patients with R/R FL. Here, we report 3-year follow-up (FU) results in patients …
View article: Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study
Effects of antibiotic prophylaxis in first-line therapy of advanced stage classic Hodgkin lymphoma: An analysis of the GHSG HD21 study Open
Introduction: The benefit of antibiotic prophylaxis (ABP) during chemotherapy for cancer remains controversial. The growing resistance to fluoroquinolones in hematological patients (Gupta et al., Lancet Oncology, 2025) and concerns about a…
Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study. Open
Background: Zamtocabtagene autoleucel (zamto-cel) is an autologous, non-cryopreserved tandem CD20-CD19 directed CAR-T cell therapy produced on the fully automated CliniMACS® Prodigy System in 12 days. Interim results from a phase II study …
Association between metabolic tumor burden and health-related quality of life in patients with classic Hodgkin lymphoma Open
Introduction Staging with [ 18 F]fluorodeoxyglucose positron emission tomography/computed tomography (PET) is standard of care in classic Hodgkin lymphoma (cHL). Metabolic tumor volume (MTV) is a quantitative biomarker of tumor burden and …
Long non-coding RNA LINC00926 is a biomarker for naïve B-cells with prognostic value in advanced stage classic Hodgkin Lymphoma Open
Not available.
Risk-factors of the Health-related Quality of Life in Hodgkin Lymphoma Patients Open
Objective: Hodgkin lymphoma survivors are at risk of experiencing persistent impairmentsin their health-related quality of life (HRQoL). This study identifies risk factors anddevelops prediction models for HRQoL of Hodgkin lymphoma patient…
Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL Open
Tisagenlecleucel is a CD19-directed autologous chimeric antigen receptor (CAR) T-cell therapy. Quantitative polymerase chain reaction assays are highly sensitive in defining in vivo kinetics by measuring CAR transgene in peripheral blood. …
View article: CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma Open
Despite the improvement, approximately 60% of patients with relapsed or refractory (r/r) aggressive B cell lymphoma (B-NHL) do not achieve durable benefit from CAR-T cell therapy. To elucidate factors associated with CAR-T therapy resistan…
View article: Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients (Auto-COVID-VACC): Protocol for Multicenter Prospective Noninterventional Study Open
Background Despite the availability of vaccines, immunocompromised patients are still at high risk for severe COVID-19. Vaccination has been proven to be an effective measure in preventing severe SARS-CoV-2 infections; however, data on B- …
Pre-phase treatment with rituximab and high-dose methotrexate to re-evaluate eligibility for intensive induction treatment of frail patients with central nervous system lymphoma Open
Not available.
View article: T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin Lymphoma Open
The Tumor Microenvironment (TME) in classical Hodgkin Lymphoma (HL) contains abundant immune cells and only few neoplastic Hodgkin and Reed-Sternberg cells (HRSC). We analyzed the T-cell receptor (TCR) repertoire to detect T-cell expansion…
Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study Open
Introduction: The German Hodgkin Study Group (GHSG) HD21 randomized trial results showed that BrECADD had a more favorable toxicity profile and higher progression-free survival than eBEACOPP. The HD21 study co-primary endpoint demonstrated…
Patterns of Disease in Early Stage Favorable Hodgkins Lymphoma Open
Background: Early stage favorable Hodgkin's Lymphoma (HL) is a curable disease. Current standard of care (SOC) consists of a combined modality treatment with a 5-year PFS of 93.4%. Previous works have shown that the location of lymph node …